Date: 2014-02-24
Type of information: Collaboration agreement
Compound: CombiCult®
Company: Plasticell (UK) JCR Pharmaceuticals (Japan)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism: CombiCult® is a combinatorial cell culture platform used in optimised stem cell differentiation protocols in regenerative medicine, cell therapy and research and development.
Disease:
Details: * On February 24, 2014, Plasticell, a UK biotechnology company specializing in stem cell differentiation, has announced that it has signed a collaboration agreement with JCR Pharmaceuticals to discover custom stem cell culture media using its award-winning combinatorial stem cell technology, CombiCult®. Under the terms of the agreement, Plasticell will use its stem cell expertise to work with JCR scientists, deploying CombiCult® to discover novel GMP-ready protocols for therapeutic applications.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
